Anti-cancer therapy-induced metabolic syndrome

Česká verzia

Authors: Eva Řiháčková ¹; Lubomír Elbl ¹; Michal Řiháček ²; Mária Holická ¹; Petr Kala ¹
Authors place of work: Interní kardiologická klinika, LF MU a FN Brno ¹; Biochemický ústav, LF MU, Brno ²
Published in the journal: Vnitř Lék 2021; 67(6): 334-338
Category: Review Articles

Summary

The increasing number of long-term survivors that underwent the anti-cancer therapy faces the late treatment-related adverse effects and the increased risk of developing metabolic syndrome. This article defines the pathophysiology that underlies development of anti-cancer therapy-related metabolic syndrome and outlines the possibility of optimisation of comprehensive care focusing on prevention. Considering the preventability of metabolic syndrome, effective screening and follow-up appropriate for patients at increased risk of related adverse events should be established. Subsequently, early initiation of therapy targeting the hallmarks of metabolic syndrome may ease its manifestation in long-term perspective.

Keywords:

metabolic syndrome – oncology – anti-cancer therapy

Zdroje

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12): 1595–607.

2. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012; 16(1): 7–12.

3. Tellechea ML, Aranguren F, Martínez-Larrad MT et al. Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. Diabetes Care. 2009; 32(7): e85.

4. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–5.

5. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17): 2735–52.

6. Lau DC, Dhillon B, Yan H et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5): H2031–41.

7. Cinti S, Mitchell G, Barbatelli G et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005; 46(11): 2347–55.

8. Bernberg E, Ulleryd MA, Johansson ME et al. Social disruption stress increases IL-6 levels and accelerates atherosclerosis in ApoE-/ – mice. Atherosclerosis. 2012; 221(2): 359–65.

9. Azzawi M, Hasleton P. Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease. Cardiovasc Res. 1999; 43(4): 850–9.

10. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004; 68(11): 975–81.

11. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24(1): 29–33.

12. Combs TP, Berg AH, Obici S et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001; 108(12): 1875–81.

13. Maahs DM, Ogden LG, Kinney GL et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005; 111(6): 747–53.

14. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14): 1730–7.

15. Stocks T, Lukanova A, Johansson M et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2008; 32(2): 304–14.

16. Kabat GC, Kim M, Chlebowski RT et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(7): 2046–53.

17. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8(9): 784–96.

18. Phillips SM, Padgett LS, Leisenring WM et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev. 2015; 24(4): 653–63.

19. Pavlík T, Májek O, Büchler T et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008. Cancer Epidemiol. 2014; 38(1): 28–34.

20. Paris C, Yates L, Lama P et al. Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents. Pediatr Blood Cancer. 2012; 59(2): 306–10.

21. Kim M, Kim IH, Lim MK et al. Increased prevalence of metabolic syndrome in adult cancer survivors: Asian first report in community setting. Cancer Epidemiol. 2019; 58: 130–6.

22. Buttros DeA, Nahas EA, Vespoli HeL et al. Risk of metabolic syndrome in postmenopausal breast cancer survivors. Menopause. 2013; 20(4): 448–54.

23. Kim SH, Cho YU, Kim SJ. Weight Gain and its Correlates among Breast Cancer Survivors. Asian Nurs Res (Korean Soc Nurs Sci). 2013; 7(4): 161–7.

24. Zee P, Chen CH. Prevalence of obesity in children after therapy for acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1986; 8(4): 294–9.

25. Talvensaari KK, Lanning M, Tapanainen P et al. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996; 81(8): 3051–5.

26. Gurney JG, Ness KK, Stovall M et al. Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab. 2003; 88(10): 4731–9.

27. Oeffinger KC, Mertens AC, Sklar CA et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003; 21(7): 1359–65.

28. Hoffman KE, Derdak J, Bernstein D et al. Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer. 2008; 50(2): 341–6.

29. Haddy TB, Mosher RB, Nunez SB et al. Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation. Pediatr Blood Cancer. 2006; 46(2): 258–61.

30. Sklar CA, Mertens AC, Walter A et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000; 35(2): 91–5.

31. Gurney JG, Ness KK, Sibley SD et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006; 107(6): 1303–1312.

32. Pietilä S, Mäkipernaa A, Sievänen H et al. Obesity and metabolic changes are common in young childhood brain tumor survivors. Pediatr Blood Cancer. 2009; 52(7): 853–9.

33. Link K, Moëll C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004; 89(10): 5003–12.

34. Follin C, Thilén U, Ahrén B et al. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2006; 91(5) 1872–5.

35. Meacham LR, Sklar CA, Li S et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med. 2009; 169(15): 1381–8.

36. van Nimwegen FA, Schaapveld M, Janus CP et al. Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma. J Clin Oncol. 2014;32(29):3257–63.

37. Friedman DN, Hilden P, Moskowitz CS et al. Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study. Pediatr Blood Cancer. 2018; 65(11): e27304.

38. Belle FN, Kasteler R, Schindera C et al. No evidence of overweight in long-term survivors of childhood cancer after glucocorticoid treatment. Cancer. 2018; 124(17): 3576–85.

39. Westerink NL, Nuver J, Lefrandt JD et al. Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Crit Rev Oncol Hematol. 2016; 108: 128–36.

40. Casco S, Soto-Vega E. Development of Metabolic Syndrome Associated to Cancer Therapy: Review. Horm Cancer. 2016; 7(5–6): 289–95.

41. Ryder M, Callahan M, Postow MA et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014; 21(2): 371–81.

42. Bu DX, Tarrio M, Maganto-Garcia E et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(5): 1100–7.

43. Sklar C, Whitton J, Mertens A et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000; 85(9): 3227–32.

44. Sanders JE, Hoffmeister PA, Woolfrey AE et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood. 2009; 113(2): 306–8.

45. Bogefors C, Isaksson S, Bobjer J, et al. Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology. 2017; 5(4): 711–7.

46. Redig AJ, Munshi HG. Care of the cancer survivor: metabolic syndrome after hormone- modifying therapy. Am J Med. 2010; 123(1): 87.e1–6.

47. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.

48. de Haas EC, Oosting SF, Lefrandt JD et al. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010; 11(2): 193–203.

49. Cohen P. Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes. Med Hypotheses. 2009; 72(2): 227–8.

50. Tonorezos ES, Robien K, Eshelman-Kent D et al. Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia. Cancer Causes Control. 2013; 24(2): 313–21.

51. Mostoufi-Moab S, Seidel K, Leisenring WM et al. Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016; 34(27): 3240–3247.